• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by DBV Technologies S.A.

    6/24/25 4:06:11 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    S-8 1 d858624ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 24, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    DBV TECHNOLOGIES S.A.

    (Exact name of registrant as specified in its charter)

     

     

     

    France   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    107 avenue de la République

    92320 Châtillon France

    +33 1 55 42 78 78

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    2025 Stock Option Plan

    2025 Free Share Plan

    (Full title of the plans)

    Michele Robertson

    DBV Technologies Inc.

    10 Independence Boulevard

    Suite 302

    Warren, New Jersey 07059

    +1 908-679-5200

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Richard Segal

    Darah Protas

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    +1 212 479 6000

     

    Arnaud Duhamel

    Gide Loyrette Nouel A.A.R.P.I.

    15 rue de Laborde

    75008 Paris France

    +33 1 40 75 00 00

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
    Emerging growth company   ☐     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of this Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by DBV Technologies S.A. (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

    (a) The contents of the Registrant’s Registration Statements on Form S-8, previously filed with the Commission on October 22, 2014 (File No. 333-199513), November  20, 2023 (File No. 333-275662) and July 2, 2024 (File No. 333-280657).

    (b) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (File No.  001-36697), filed with the Commission on April 11, 2025, the Amendment No. 1 to the Registrant’s Annual Report on From 10-K (File No. 001-36697) for the fiscal year ended December  31, 2024, filed with the Commission on April 28, 2025 and the Amendment No. 2 to the Registrant’s Annual Report on From 10-K (File No. 001-36697) for the fiscal year ended December  31, 2024, filed with the Commission on May 14, 2025;

    (c) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (File No. 001-36697), filed with the Commission on April 30, 2025;

    (d) The Company’s Current Reports on Form 8-K filed with the Commission on March 24, 2025, March  31, 2025 and June 11, 2025 (in each case, except for information contained therein which is furnished rather than filed); and

    (e) The description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission under Section  12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on October 17, 2014 (File No. 001-36697), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents filed, but not furnished, by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered under this Registration Statement have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. In no event, however, will any of the information, including exhibits, that the Registrant discloses under Item 2.02 and Item 7.01 of any report on Form 8-K that has been or may be, from time to time, furnished to the Commission, be incorporated by reference into or otherwise become a part of this Registration Statement.

    Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 4. DESCRIPTION OF SECURITIES

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Under French law, provisions of by-laws that limit the liability of directors are prohibited. However, French law allows sociétés anonymes to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good faith and within their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance.

    The Registrant maintains liability insurance for its directors and officers, including insurance against liability under the Securities Act of 1933, as amended, and the Registrant has entered into agreements with its directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements to provide for indemnification for damages and expenses including, among other things, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that capacity. The Registrant believes that this insurance and these agreements are necessary to attract qualified directors and executive officers.

    These agreements may discourage shareholders from bringing a lawsuit against the Registrant’s directors and executive officers for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit the Registrant and its shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent the Registrant pays the costs of settlement and damage awards against directors and officers pursuant to these insurance agreements.

    Certain of the Registrant’s non-employee directors may, through their relationships with their employers or partnerships, be insured against certain liabilities in their capacity as members of the Registrant’s board of directors.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.

    ITEM 8. EXHIBITS

     

                     Incorporated by Reference
    Exhibit
    Number
       Description    Schedule
    Form
         File Number      Exhibit    Filing Date
     4.1+    Amended and Restated Bylaws (statuts) of the Registrant (English translation)            
     4.2    Form of Amendment No. 1 to Deposit Agreement      F-6 POS        333-266202      99(a)(i)    May 17, 2024
     4.4    Form of Amendment No. 2 to Deposit Agreement      F-6 POS        333-266202      99(a)(i)    November 12, 2024
     4.5    Form of American Depositary Receipt (included in Exhibit 4.4)      F-6 POS        333-266202      99(a)(ii)    November 12, 2024


     5.1+    Opinion of Gide Loyrette Nouel A.A.R.P.I., French counsel to the Registrant            
    23.1+    Consent of Deloitte & Associés            
    23.2+    Consent of KPMG S.A.            
    24.1+    Power of Attorney (included on the signature page of this Form S-8).            
    99.1+    2025 Stock Option Plan (English translation)            
    99.2+    2025 Free Share Plan (English translation)            
    107+    Calculation of Filing Fee Table            
     

     

    +

    Filed herewith.

    ITEM 9. UNDERTAKINGS

     

    A.

    The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Châtillon, France on June 24, 2025.

     

    DBV TECHNOLOGIES S.A.
    By:   /s/ Daniel Tassé
      Daniel Tassé
      Chief Executive Officer

    POWER OF ATTORNEY

    We, the undersigned directors, officers and/or authorized representative in the United States of DBV Technologies S.A., hereby severally constitute and appoint Daniel Tassé and Virginie Boucinha, and each of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of DBV Technologies S.A., and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated on June 24, 2025.

     

    Signature    Title

    /s/ Daniel Tassé

    Daniel Tassé

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

    /s/ Virginie Boucinha

    Virginie Boucinha

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    /s/ Michel de Rosen

    Michel de Rosen

       Director

    /s/ Mailys Ferrere

    Mailys Ferrere

       Director

    /s/ Michael J. Goller

    Michael J. Goller

       Director


    /s/ Danièle Guyot-Caparros

    Danièle Guyot-Caparros

      

    Director

    /s/ Timothy E. Morris

    Timothy E. Morris

      

    Director

    /s/ Adora Ndu

    Adora Ndu

      

    Director

    /s/ Julie O’Neill

    Julie O’Neill

      

    Director

    /s/ Ravi Madduri Rao

    Ravi Madduri Rao

      

    Director

    /s/ Daniel Soland

    Daniel Soland

      

    Director

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of DBV Technologies S.A. has signed this Registration Statement on June 24, 2025.

     

    DBV TECHNOLOGIES INC.
    By:   /s/ Michele Robertson
    Name:   Michele Robertson
    Title:   Chief Legal Officer, Vice President
    Get the next $DBVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    9/14/2021Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      3/11/24 4:15:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      2/8/24 5:02:03 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Mohideen Pharis sold $730 worth of Ordinary Shares (397 units at $1.84), decreasing direct ownership by 0.36% to 110,113 units (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      5/27/25 4:10:06 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Epic Bpifrance claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      5/20/25 4:01:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Bpifrance Investissement S.A.S. claimed ownership of 226,133 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      4/24/25 4:01:16 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    SEC Filings

    See more
    • SEC Form S-8 filed by DBV Technologies S.A.

      S-8 - DBV Technologies S.A. (0001613780) (Filer)

      6/24/25 4:06:11 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/11/25 4:05:24 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by DBV Technologies S.A.

      EFFECT - DBV Technologies S.A. (0001613780) (Filer)

      5/30/25 12:15:17 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on DBV Technologies with a new price target

      Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

      5/29/25 8:17:33 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies upgraded by Societe Generale

      Societe Generale upgraded DBV Technologies from Hold to Buy

      1/4/23 7:23:06 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies downgraded by Goldman

      Goldman downgraded DBV Technologies from Neutral to Sell

      12/16/22 7:41:19 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DBV Technologies to Participate in Upcoming EAACI Congress 2025

      Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the reduced rate of reactions from accidental peanut consumption (APC) with the VIASKIN® peanut patch versus placebo in Year 2 of the Company's EPITOPE open-label extension (OLE) trial, as w

      6/12/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

      Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/. About DBV TechnologiesDB

      6/11/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

                                                              Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights05/30/2025136,973,697Total gross of voting rights: 136,973,697Total net* of voting rights: 136,738,528 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

      6/4/25 4:32:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Financials

    Live finance-specific insights

    See more
    • DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

      Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

      1/8/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

      Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod

      12/11/24 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

      Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025  European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7

      10/22/24 4:45:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    See more
    • DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

      Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent

      5/7/24 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

      Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech

      10/16/23 2:00:00 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

      Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October

      10/3/22 4:30:00 PM ET
      $AQST
      $DBVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      11/14/24 4:55:56 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 8:56:45 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 4:06:12 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care